NASDAQ:CYTH - Cyclo Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $25.00
  • Forecasted Upside: 256.13 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$7.02
▲ +0.44 (6.69%)
1 month | 3 months | 12 months
Get New Cyclo Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CYTH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CYTH

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$25.00
▲ +256.13% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Cyclo Therapeutics in the last 3 months. The average price target is $25.00, with a high forecast of $25.00 and a low forecast of $25.00. The average price target represents a 256.13% upside from the last price of $7.02.
Buy
The current consensus among 1 polled investment analysts is to buy stock in Cyclo Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/29/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/25/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/23/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/21/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/22/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/10/2021Maxim GroupBoost Price TargetPositive ➝ Buy$12.00 ➝ $25.00Low
i
12/17/2020Maxim GroupInitiated CoverageBuy$12.00High
i
(Data available from 4/21/2016 forward)
Cyclo Therapeutics logo
Cyclo Therapeutics, Inc., a biotechnology company, develops cyclodextrin-based products for the treatment of diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug for the treatment of Niemann-Pick Type C disease. The company also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. It has a collaboration with the Chattanooga Center for Neurologic Research. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in October 2019. Cyclo Therapeutics, Inc. was founded in 1990 and is based in Gainesville, Florida.
Read More

Today's Range

Now: $7.02
$6.51
$7.12

50 Day Range

MA: $8.78
$6.58
$12.56

52 Week Range

Now: $7.02
$3.55
$17.75

Volume

185,234 shs

Average Volume

986,842 shs

Market Capitalization

$44.18 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Cyclo Therapeutics?

The following equities research analysts have issued stock ratings on Cyclo Therapeutics in the last year: Maxim Group.
View the latest analyst ratings for CYTH.

What is the current price target for Cyclo Therapeutics?

1 Wall Street analysts have set twelve-month price targets for Cyclo Therapeutics in the last year. Their average twelve-month price target is $25.00, suggesting a possible upside of 256.1%. Maxim Group has the highest price target set, predicting CYTH will reach $25.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $25.00 for Cyclo Therapeutics in the next year.
View the latest price targets for CYTH.

What is the current consensus analyst rating for Cyclo Therapeutics?

Cyclo Therapeutics currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CYTH will outperform the market and that investors should add to their positions of Cyclo Therapeutics.
View the latest ratings for CYTH.

What other companies compete with Cyclo Therapeutics?

How do I contact Cyclo Therapeutics' investor relations team?

Cyclo Therapeutics' physical mailing address is 6714 NW 16TH STREET SUITE B, GAINSVILLE FL, 32653. The company's listed phone number is 386 418 8060 and its investor relations email address is [email protected] The official website for Cyclo Therapeutics is www.ctd-holdings.com.